D68.32
D68.32: Hemorrhagic disorder due to extrinsic circulating anticoagulants
Billable / specific codeICD-10-CM
D68.32 is a billable, specific ICD-10-CM code for hemorrhagic disorder due to extrinsic circulating anticoagulants. It is valid for submission on a claim.
Check D68.32 with the rest of the claim: free scrubberUse additional code
Add a secondary code to capture the detail described below.
Inclusion terms
Alternative wordings a physician may use in the chart for this same code.
- Drug-induced hemorrhagic disorder
- Hemorrhagic disorder due to increase in anti-IIa
- Hemorrhagic disorder due to increase in anti-Xa
- Hyperheparinemia
Excludes1 inherited from the categories above D68.32
A category’s note binds every code beneath it.
Excludes2 inherited from the categories above D68.32
Not part of this code, but both may be coded when both are present.
Other codes that can never be billed with D68.32
Their own Excludes1 notes name this code, so the conflict is not listed above.
- R79.1Abnormal coagulation profile
Risk adjustment
No CMS-HCC V28 category: this code does not change a RAF score.
Medicare coverage
D68.32 is named in 4 Medicare coverage policies: 4 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A55639Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions
- A56416Billing and Coding: Assays for Vitamins and Metabolic Function
- A57954Billing and Coding: Routine Foot Care
- A59101Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars
Alphabetic index entries that lead here
- Hyperheparinemia
- Anticoagulant, circulating›drug-induced(extrinsic)
- Anticoagulant, circulating›iatrogenic
- Circulating anticoagulants›due to drugs
- Disorder›drug induced hemorrhagic
- Disorder›hemorrhagic NEC›drug-induced
- Disorder›hemorrhagic NEC›due to›extrinsic circulating anticoagulants
- Disorder›hemorrhagic NEC›due to›increase in›anti-IIa
- Disorder›hemorrhagic NEC›due to›increase in›anti-Xa
Code history
Unchanged in every release from FY2024 to FY2027.